Video

ASCO 2020 Data Updates: Metastatic HER2+ Breast Cancer

Key opinion leaders discuss various trial data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting regarding the management of metastatic HER2-positive breast cancer.

Data from the following clinical trials is discussed:

  • Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).(Lin, ASCO 2020 Abstract 1005)

  • The recent FDA approvals for relapsed refractory HER2+ MBC:
    • Trastuzumab deruxtecan in Previously Treated HER2+ Breast Cancer: DESTINY-BREAST01 (Modi, NEJM 2020)

    • Fam-trastuzumab deruxtecan-nxki

    • Tucatinib

    • Neratinib

  • The potential role of trastuzumab deruxtecan in HER2-low expressing tumors: phase 3, DESTINY-Breast04; NCT03734029

Related Videos
Ruth M. O’Regan, MD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Sheldon M. Feldman, MD
Dana Zakalik, MD
Alberto Montero, MD, MBA, CPHQ
Jairam Krishnamurthy, MD, FACP
Deena Mary Atieh Graham, MD
Sheldon M. Feldman, MD
Sheldon M. Feldman, MD
In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer, highlighting the need for holistic care that addresses both physiological and psychological aspects of treatment while reinforcing the value of strong relationships between primary care physicians and specialists.